Kane Biotech Announces Improved Third Quarter 2023 Financial Results
28 nov. 2023 16h05 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its third quarter 2023 financial results. Third...
Kane Biotech to Release Third Quarter 2023 Financial Results on November 28, 2023 – Conference Call to Follow
21 nov. 2023 07h45 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and...
Kane Biotech Strengthens Board with Biotech Executive
16 nov. 2023 13h45 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech” or “Kane”) is pleased to announce that John Coleman has been...
Kane Biotech and ProgenaCare Global Launch Newly Rebranded revyve™ Antimicrobial Wound Gel at Advanced Wound Care Fall Forum
02 nov. 2023 11h48 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) in partnership with ProgenaCare Global LLP (“ProgenaCare”) today...
Kane Biotech to Release First Quarter 2023 Financial Results on May 25, 2023 – Conference Call to Follow
18 mai 2023 16h05 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, May 18, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and...
Kane Biotech Announces Distribution Agreement with ProgenaCare Global for its coactiv+™ Antimicrobial Wound Gel
20 avr. 2023 07h30 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, April 20, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announced today that it has signed a distribution agreement...
Kane Biotech Announces Additional coactiv+™ Animal Health Licensing Agreement
18 avr. 2023 07h30 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, April 18, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company”, “Kane” or “Kane Biotech”) announces that it has signed a licensing agreement with...
Kane Biotech to Release Third Quarter 2022 Financial Results on November 24, 2022 – Conference Call to Follow
17 nov. 2022 08h30 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and...
Kane Biotech Announces 510(k) Submission for its coactiv+™ Antimicrobial Hydrogel
03 nov. 2022 07h30 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that it has recently submitted a 510(k) premarket...
Kane Biotech to Release First Quarter 2022 Financial Results on May 26 – Conference Call to Follow
19 mai 2022 08h30 HE
|
Kane Biotech Inc.
WINNIPEG, Manitoba, May 19, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”), a biotechnology company engaged in the research, development and...